Loading clinical trials...
Loading clinical trials...
A Multi-indication, Single-treatment Arm, Open-label Phase 2 Study of Regorafenib and Nivolumab in Combination in Patients With Recurrent or Metastatic Solid Tumors
Conditions
Interventions
Regorafenib, (Stivarga, BAY73-4506)
Nivolumab (Opdivo)
Locations
34
United States
City of Hope - Duarte Cancer Center
Duarte, California, United States
Rocky Mountain Cancer Centers / Aurora, CO
Aurora, Colorado, United States
Moffitt Cancer Center
Tampa, Florida, United States
Sarah Cannon Cancer Center
Nashville, Tennessee, United States
Baylor Charles A. Sammons Cancer Center at Dallas
Dallas, Texas, United States
University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Start Date
February 3, 2021
Primary Completion Date
March 9, 2023
Completion Date
March 29, 2024
Last Updated
April 18, 2025
NCT06898450
NCT06658951
NCT05719558
NCT05101070
NCT06716138
NCT06307795
Lead Sponsor
Bayer
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions